These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16051478)

  • 1. Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.
    Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
    Eur J Cancer; 2005 Aug; 41(12):1824-30. PubMed ID: 16051478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
    Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
    Keller G; Schally AV; Nagy A; Halmos G; Baker B; Engel JB
    Cancer; 2005 Nov; 104(10):2266-74. PubMed ID: 16211544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins.
    Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
    Endocr Relat Cancer; 2005 Dec; 12(4):999-1009. PubMed ID: 16322338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
    Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
    Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
    Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
    Cancer; 2005 Sep; 104(6):1312-21. PubMed ID: 16047355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
    Szepeshazi K; Schally AV; Nagy A; Wagner BW; Bajo AM; Halmos G
    Cancer; 2003 Oct; 98(7):1401-10. PubMed ID: 14508826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
    Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
    Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers.
    Stangelberger A; Schally AV; Letsch M; Szepeshazi K; Nagy A; Halmos G; Kanashiro CA; Corey E; Vessella R
    Int J Cancer; 2006 Jan; 118(1):222-9. PubMed ID: 16003723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.
    Kiaris H; Schally AV; Nagy A; Sun B; Armatis P; Szepeshazi K
    Br J Cancer; 1999 Nov; 81(6):966-71. PubMed ID: 10576652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Eur J Cancer; 2005 Sep; 41(14):2196-202. PubMed ID: 16182122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
    Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L
    Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
    Keller G; Schally AV; Nagy A; Baker B; Halmos G; Engel JB
    Int J Oncol; 2006 Jun; 28(6):1507-13. PubMed ID: 16685451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
    Szepeshazi K; Schally AV; Halmos G
    Int J Oncol; 2007 Jun; 30(6):1485-92. PubMed ID: 17487370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.
    Szereday Z; Schally AV; Nagy A; Plonowski A; Bajo AM; Halmos G; Szepeshazi K; Groot K
    Br J Cancer; 2002 Apr; 86(8):1322-7. PubMed ID: 11953892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
    Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
    Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.